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ABSTRACT
RAD18, a RING-type ubiquitin ligase (E3) that plays
an essential role in post-replication repair, pos-
sesses distinct domains named RING, UBZ, SAP
and the RAD6-binding domain (R6BD) and forms a
dimer. RAD6, an ubiquitin-conjugating enzyme (E2),
stably associates with R6BD in the C-terminal
portion. In this study, we established a method to
distinguish between the two subunits of RAD18 by
introduction of different tags, and analyzed mutant
complexes. Our results, surprisingly, demonstrate
that RAD6A and RAD18 form a ternary complex,
RAD6A–(RAD18)2 and the presence of only one
R6BD in the two RAD18 subunits is sufficient for
ternary complex formation and the ligase activity.
Interestingly, ligase activity of a mutant dimer
lacking both R6BDs is not restored even with large
amounts of RAD6A added in solution, suggesting a
requirement for precise juxtaposition via interaction
with R6BD. We further show that mutations in both
subunits of either RING or SAP, but not UBZ,
strongly reduce ligase activity, although inactivation
in only one of two subunits is without effect. These
results suggest an asymmetric nature of the two
RAD18 subunits in the complex.
INTRODUCTION
Ubiquitin ligases (E3s) catalyze the transfer of ubiquitin
from E2 (ubiquitin-conjugating enzyme)–ubiquitin conju-
gates to lysine residues in target proteins. A subset of E3s
contains a RING (really interesting new gene) domain,
which binds to E2–ubiquitin conjugates and seems to
activate thioester bonds (1,2). Some RING-type E3s are
known to form heterodimers such as BRCA1–BARD1
(3–5), Ring1b-Bmi1 (6,7) and MDM2–MDMX (8–10),
while others like cIAP2 (11) and RNF4 (12) act as homo-
dimers. The heterodimeric RING-type E3s are composed
of active and inactive RING domains, and dimerization
enhances the ligase activity, suggesting that the pairing
itself is very important for enzyme function (5,6,9).
Through a RAD6-binding domain (R6BD) located in
its C-terminal region, the RAD18 RING-type ubiquitin
ligase forms a stable complex with a speciﬁc E2, RAD6
(13–17). Since RAD6 also contacts the RING domain
near the N-terminal of RAD18 for catalytic function
(2,15,18), it could interact with two distinct domains of
RAD18 simultaneously. Such interactions between an
E2 and an E3 are quite unique to RAD6–RAD18.
Recently, it has been reported that interaction
between R6BD and RAD6 blocks the intrinsic activity
of RAD6 in forming ubiquitin chains, ensuring mono-
ubiquitination of PCNA (19). Previous studies have also
reported that RAD18 forms a dimer and suggested the
RAD6–RAD18 complex to be a dimer of RAD6–
RAD18 heterodimer (15,20,21), hereafter designated as
(RAD6–RAD18)2.
RAD6 and RAD18 play an essential role in post-
replication repair of damaged DNA via ubiquitination of
proliferating cell nuclear antigen (PCNA) at Lys164
(22,23). The RAD6–RAD18 complex itself catalyzes
mono-ubiquitination of PCNA in vitro (24–28). The
mono-ubiquitinated PCNA appears to enhance lesion by-
pass replication by stimulation of entry of translesion
DNA polymerases at stalled 30-ends, through interactions
between ubiquitin-binding domains of the polymerases
and ubiquitin moieties of mono-ubiquitinated PCNA
(24,26,29–31). Furthermore, RAD18 features a pol
Z-binding domain that is important for recruiting pol Z
to stalled 30-ends (17,32).
RAD18 has two other domains UBZ (ubiquitin-binding
zinc ﬁnger) (33–35) and SAP (SAF-A/B, Acinus and
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tion of RAD18 at damage sites (34,37,39) and has afﬁnity
for Ub chains (33,34) suggesting speciﬁc binding to
damage-associated poly-ubiquitinated proteins (39). The
SAP domain possesses DNA-binding activity (15,38),
although it appears to be unnecessary for accumulation
of RAD18 at damage sites (37,39). Rather, it is crucial for
pol Z focus formation (37) possibly depending on PCNA
ubiquitination, which is attributed to an essential role of
the SAP domain in ligase activity (38,39).
Although multiple domains of RAD18 are clearly con-
cerned with ligase activity, it is unknown how the distinct
entities of the two RAD18 subunits interact with each
other for enzyme function. In the present study, we estab-
lished a method to analyze the structure and functions of
the human RAD6A–RAD18 complex and demonstrated
an asymmetric nature of the two RAD18 molecules in the
complex.
MATERIALS AND METHODS
Plasmids
Expression plasmids for RAD6A–RAD18, E1, ubiquitin,
PCNA and RFC were as described previously (26,40–42).
For overproduction of human RAD6A,
RAD6A–
HisRAD18,
FLAGRAD6A–
HisRAD18, the genes
were cloned into pET20b(+) (Novagen) to yield pET-
RAD6A and pET-RAD6A/hisRAD18, pET-ﬂagRAD6A/
hisRAD18, respectively. To make an expression plasmid
compatible with pET plasmids in Escherichia coli
cells, the entire coding unit of pET-RAD6A/RAD18
(42) was cloned into pACYC Duet1 (Novagen) to
yield pAC-RAD6A/RAD18. Expression plasmids for
overproduction of RAD6A–
FLAGRAD18 and
FLAGRAD6A–
FLAGRAD18, pAC-RAD6A/ﬂagRAD18
and pAC-ﬂagRAD6A/ﬂagRAD18 were generated, re-
spectively. In those plasmids, His-tagged sequences were
taken from pET15 and all tagged sequences were attached
to immediately before the start codons of the respective
genes. Expression plasmids in human cells for RAD6 were
cloned in pCMV, and for RAD18 in pCDNA3 ﬂag and
pCAGGS (43).
Proteins
Proteins used in this study were overproduced in E. coli
cells. During all puriﬁcation steps, monitoring was done
by SDS–PAGE followed by staining with Coomassie
Brilliant Blue R-250 (CBB), or western blotting. Protein
concentrations were determined by Bio-Rad protein assay
using BSA (Bio-Rad) as the standard. PCNA, RFC, E1,
ubiquitin and RAD6A–RAD18 complex were puriﬁed as
described previously (26,40,41). Detailed procedures for
puriﬁcation of recombinant proteins established in this
study are described in Supplementary Data.
Sucrose density gradient sedimentation
Sucrose density gradient sedimentation was performed as
described earlier (44). Puriﬁed RAD6A–RAD18
complexes (1.7mg), were sedimented through 2ml of
10–40% sucrose gradient in buffer A containing 300mM
NaCl by centrifugation at 55000 rpm for 20h in a TLS 55
rotor (Beckman) at 4 C and fractions (100ml) were col-
lected from the bottom of the tube and analyzed by SDS–
PAGE. Gel bands were stained with CBB and quantiﬁed
using Multi Gauge software Version 3.0 (FUJIFILM).
Sedimentation coefﬁcients were determined relative to
those of standard proteins sedimented in parallel
gradients.
Antibodies
To obtain polyclonal antibodies against RAD18, trun-
cated His-tagged RAD18 proteins (127–255 amino acids)
were expressed in BL21 (DE3) (45), puriﬁed and used to
immunize rabbits. Anti-Penta-His monoclonal (Qiagen,
34660), anti-FLAG M2 monoclonal (Sigma, F3165),
anti-RAD6 polyclonal (Abcam, ab31917) and anti-
PCNA polyclonal (Santa Cruz, sc-7907) antibodies were
purchased.
PCNA-mono-ubiquitination assays
The standard reaction mixture (25ml) contained 20mM
HEPES–NaOH (pH 7.5), 50mM NaCl, 0.2mg/ml BSA,
1mM DTT, 10mM MgCl2, 1mM ATP, 100ng poly(dA)-
oligo(dT), PCNA (1pmol), RFC (350fmol), E1
(850fmol), ubiquitin (170pmol) and the indicated amounts
of RAD6A–RAD18 complex. Reaction mixtures were pre-
pared on ice then incubated at 30 C for 10min. The reac-
tions were terminated by addition of 2  SDS sample
buffer containing 25mM EDTA. Ubiquitination of
PCNA was assessed by western analysis, detected by an
ECL chemiluminescence kit (GE Healthcare Life Science).
RESULTS
Physicochemical properties of the human RAD6A–RAD18
complex
To study the subunit composition of RAD6A–RAD18
complex, we ﬁrst determined the Stokes’ radius and sedi-
mentation coefﬁcient of the puriﬁed RAD6A–RAD18
complex (26) by gel ﬁltration and sucrose density
gradient centrifugation, respectively (Table 1). The
obtained value of Stokes’ radius (62A ˚ ) corresponds to
an apparent molecular mass of 490 kDa, but that of the
Table 1. Physicochemical properties of the RAD6A–RAD18 complex
Stokes’
radius
a (A ˚ )
Sedimentation
coefﬁcient
b  10
 13s( S 20,w)
Molecular
mass
c (kDa)
62 5.0 131
aDetermined by Superdex 200 gel ﬁltration using the size markers
ferritin (61.0A ˚ ), aldolase (48.1A ˚ ), albumin (35.5A ˚ ) ovalbumin
(30.5A ˚ ) and ribonuclease A (16.4A ˚ ), and the data were based on
A280 values monitored during the chromatography.
bDetermined with ferritin (17.6S), catalase (11.3S), aldolase (7.4S),
albumin (4.2S) and ribonuclease A (1.8S) as standards, and the data
were based on the SDS–PAGE gel proﬁle.
cEstimated from the Stokes’ radius and the sedimentation coefﬁcient
assuming a partial speciﬁc volume of 0.73 (46).
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apparent molecular mass of 70kDa. The large difference
between these two values suggests that the complex does
not have a compact globular shape. Employing the
method described by Siegel and Monty (46), we estimated
the molecular mass of the RAD6A–RAD18 complex to be
131kDa (Table 1). Since calculated molecular masses of
RAD6A and RAD18 are 17.3 and 56.2kDa, respectively,
the total of molecular mass should be 73.5kDa for
RAD6A–RAD18 and 147kDa for (RAD6A–RAD18)2.
Although the value estimated from the experiments was
close to that of (RAD6A–RAD18)2, we further
investigated the stoichiometry of RAD6A and RAD18
in the complex.
Direct evidence that the RAD6A–RAD18 complex
contains two RAD18 molecules
To obtain direct evidence that the RAD6A–RAD18
complex contains two molecules of RAD18, we
co-expressed both His-tagged RAD18 and FLAG-tagged
RAD18 genes together with RAD6A gene in the same
E. coli cells. Three different complexes containing
HisRAD18–
HisRAD18,
FLAGRAD18–
FLAGRAD18 or
HisRAD18–
FLAGRAD18 would be expected if we assume
that the complex should contain two molecules of
RAD18. When the cell lysate was loaded to a
Ni-chelating column, we found some
FLAGRAD18 to be
absorbed to the column and eluted together with approxi-
mately equal amounts of
HisRAD18 at a lower imidazole
concentration (Figure 1A, lane 2), whereas the remainder
of the
HisRAD18 was eluted at a higher imidazole concen-
tration (see Supplementary Materials and Methods
section). Since it was expected that the former was
HisRAD18–
FLAGRAD18 hetero complex and the latter
was
HisRAD18 homo complex, the former was further
puriﬁed through a heparin column (Figure 1A, lane 3)
and analyzed by gel ﬁltration (Figure 1A, lane 4). The
elution proﬁle was the same as that of untagged
RAD6A–RAD18 complex (Table 1 and see also
Figure 6C), suggesting the tag sequences do not affect
the overall structure of the complex. While western
blotting with anti-Penta-His and anti-FLAG antibodies
speciﬁcally detected
HisRAD18 and
FLAGRAD18
proteins, respectively (Figure 1B), blotting with anti-
RAD18 antibodies detected the two proteins equally,
thereby indicating that the puriﬁed complex contains
HisRAD18 and
FLAGRAD18 at a 1:1 ratio. To further
verify that RAD6A,
HisRAD18 and
FLAGRAD18 form a
complex, a fraction eluted from gel ﬁltration was applied
to FLAG-afﬁnity chromatography. The result demonst-
rated that the three proteins were adsorbed to the
anti-FLAG M2 afﬁnity gel and eluted with the FLAG
peptide (Figure 1A, lane 5). We thus conclude that the
RAD6A–RAD18 complex contains two RAD18
molecules.
Subunit composition of the RAD6A–RAD18 complex is
RAD6A–(RAD18)2
To examine the stoichiometry of RAD6A in the com-
plex, we directly compared amounts of RAD6A in the
complex with puriﬁed RAD6A protein as a reference.
We applied 500ng of the puriﬁed complex,
RAD6A–
HisRAD18–
FLAGRAD18, in parallel with differ-
ent amounts (65 or 115ng) of RAD6A monomers to SDS–
PAGE. The amounts of RAD6A in the complex should be
65 or 115ng, if the complex is RAD6A–(RAD18)2 or
(RAD6A–RAD18)2, respectively (Figure 2A). The
results of CBB staining and western blotting showed the
amount of RAD6A in the complex to be closer to 65ng
(Figure 2A), thus suggesting that the complex contains
RAD6A and RAD18 at the ratio of 1:2. To conﬁrm
this, the FLAG-tag was introduced to RAD6A and the
FLAGRAD6A–
HisRAD18–
FLAGRAD18 complex was puri-
ﬁed as described above. We applied 505ng of the puri-
ﬁed complex to SDS–PAGE, in parallel with 500ng
of RAD6A–
HisRAD18–
FLAGRAD18 as a reference
(Figure 2B). Western blotting with anti-RAD6 antibodies
conﬁrmed that both complexes contained equivalent
amounts of RAD6A (Figure 2B), and blotting with an
anti-FLAG antibody clearly demonstrated that the mo-
lecular ratio of
FLAGRAD6A and
FLAGRAD18 was 1:1
(Figure 2B), suggesting strongly the ratio of RAD6A to
RAD18 to be 1:2.
R6BD is located within amino acid residues 340–395 of
RAD18 (Figure 3D) (17,19). Using a deletion mutant con-
sisting of amino acid residues 1–341 of RAD18 (hereafter
designated as RAD18
C1, Figure 3D), we further exa-
mined the stoichiometry of RAD6 and RAD18. When
HisRAD18
C1 and
FLAGRAD18
C1 were co-produced
with RAD6A in the same E. coli cells, a complex contain-
ing
HisRAD18
C1 and
FLAGRAD18
C1 was puriﬁed simi-
larly as described above, but it did not contain RAD6A
(Figure 2C, lane 3). This result indicates that the R6BD
is required for complex formation with RAD6 but is
dispensable for dimerization. In contrast, when
HisRAD18
C1 was co-produced with
FLAGRAD18 and
RAD6A in the same E. coli cells, we successfully obtained
a RAD6A–
HisRAD18
C1–
FLAGRAD18 ternary complex
kDa 23 1 M
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Figure 1. Puriﬁcation of the RAD6A–
HisRAD18–
FLAGRAD18
complex. (A) Pooled fractions eluted from respective columns were
analyzed by SDS–PAGE followed by staining with CBB. Lane 1, cell
lysate; lane 2, Ni-chelating column; lane 3, heparin column; lane 4,
gel-ﬁltration column; lane 5, anti-FLAG afﬁnity column. Molecular
masses of each marker (lane M) are shown to the left of the gel. (B)
Western analysis of the pooled fraction eluted from the gel ﬁltration
column. Membranes were probed with the indicated antibodies.
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two RAD18 subunits could form the complex with
RAD6A. Again, amounts of each protein in these com-
plexes were compared by CBB staining and western blott-
ing. For Figure 2C, we applied 500ng of
RAD6A–
HisRAD18–
FLAGRAD18 (lane 1) and 432ng of
the RAD6A–
HisRAD18
C1–
FLAGRAD18 complex (lane 2)
to SDS–PAGE. If stoichiometry of each component were
1:1:1 in both complexes, amounts of each
FLAGRAD18
and each RAD6A in the two complexes should be identi-
cal (Figure 2C). The results of CBB staining and western
blotting proved to be in good agreement with our estima-
tions (Figure 2C, lanes 1 and 2), suggesting that the
RAD18 dimer, as well as the RAD18 monomer, is
capable of accommodating only one RAD6 molecule
(Figure 2D). Very interestingly, the hetero complex
RAD6A–(
HisRAD18
C1–
FLAGRAD18) was catalytically
active in terms of PCNA ubiquitination (Figure 2E). As
expected,
HisRAD18
C1–
FLAGRAD18
C1 was inactive
(Figure 2E), and its ligase activity was hardly restored
by addition of excess amounts of RAD6A in solution
(Figure 2F). To see whether the defect is due to the loss
of function of the C-terminal portion, another truncated
RAD18 mutant consisting of amino acid residues 1–388
(hereafter designated as RAD18
C2, Figure 3D), was
examined. It was expected that RAD18
C2 could form a
G
A C B
E
F
D
Figure 2. Subunit composition of the RAD6A–RAD18 complex and deletion analysis of RAD18. (A) The indicated amounts of puriﬁed RAD6A–
RAD18 complex and RAD6A were analyzed by SDS–PAGE followed by staining with CBB and western blotting probed with anti-RAD6
antibodies. Relative chemiluminescence signals detected with a CCD camera are shown. Amounts of each subunit calculated for two different
postulated subunit compositions are shown in the table. (B and C) Indicated amounts of puriﬁed RAD6A–RAD18 complexes were analyzed by
SDS–PAGE followed by staining with CBB and western blotting probed with anti-FLAG and anti-RAD6 antibodies. Relative chemiluminescence
signals detected with a CCD camera are shown. Amounts of each subunit calculated for the postulated subunit compositions are shown in the tables.
(D) Schematic representations of the structures for respective RAD6A–RAD18 complexes. (E) Ligase activities of the respective RAD6A–RAD18
complexes. Increasing amounts of the complexes (0.5, 1 and 2pmol) were subjected to standard assays. The reaction products were analyzed by
western blotting with anti PCNA antibodies. I, RAD6A–(
HisRAD18–
FLAGRAD18); II, RAD6A–(
HisRAD18
C1–
FLAGRAD18); III,
HisRAD18
C1–
FLAGRAD18
C1.( F) Titration of RAD6A in the reaction with
HisRAD18
C1–
FLAGRAD18
C1. Indicated amounts of RAD6A
were incubated with 2pmol of
HisRAD18
C1–
FLAGRAD18
C1 (III) under standard assay conditions. As control reactions, 1pmol of RAD6A–
(
HisRAD18–
FLAGRAD18) (I) was incubated in the presence or absence of additional RAD6A. (G) Analysis of complex formation and ligase activity
of another C-terminal deletion mutant of RAD18. Puriﬁed complexes (3.7pmol as a trimer) were analyzed by SDS–PAGE followed by staining with
CBB. Lane 1, RAD6A–(
HisRAD18–
FLAGRAD18) (I); lane 2, RAD6A–(
HisRAD18
C2–
FLAGRAD18
C2) (IV). Structure of the mutant complex (IV)
was represented schematically. Assays were performed as described in (E).
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(15). Indeed, it was successfully reconstituted into a ternary
complex, RAD6A–
HisRAD18
C2–
FLAGRAD18
C2,a n dt h e
complex exhibited ligase activity similar to the wild-type
level (Figure 2G), indicating that the C-terminal region of
389–495 amino acid residues is dispensable for ligase
activity. From all these results (Figures 1 and 2),
together with the fact that RAD6 is essentially a
monomer (see Supplementary Materials and Methods
section) (19,47), we conclude the subunit composition of
the RAD6A–RAD18 complex to be RAD6A–(RAD18)2
with a molecular mass of 130kDa. Thus, the overall struc-
ture of the complex is asymmetric. Notably, this
well matched the 131kDa estimated molecular mass
from the Stokes’ radius and the sedimentation coefﬁcient
(Table 1).
Evidence of the ternary complex, RAD6A–(RAD18)2,
in vivo
To obtain evidence of ternary complex formation
in vivo, HA-tagged RAD6A and FLAG-tagged RAD18
were expressed together in human cells, and
HARAD6A–
FLAGRAD18 complexes were isolated using
FLAG afﬁnity and then HA afﬁnity gels. The complexes
were a mixture of unmodiﬁed RAD18 and mono-
ubiquitinated RAD18, as reported previously (Figure 4A)
(48). Subunit composition of the puriﬁed complexes was
determined by western blotting with anti-RAD6 and
anti-RAD18 antibodies using RAD6A–(RAD18)2
complex puriﬁed from E. coli cells (26) as references.
Ratio of signals from
HARAD6A and
FLAGRAD18
well ﬁtted those from RAD6A–(RAD18)2 complexes
(Figure 4A), suggesting the subunit composition to be
RAD6A–(RAD18)2. This was further conﬁrmed using
partially puriﬁed untagged RAD6A–RAD18 complexes
generated by conventional column chromatography
from RAD6A and RAD18 expressing human cells. We
found that RAD6A, RAD18 and mono-ubiquitinated
RAD18 all eluted together from a gel ﬁltration column
(Figure 4B), similar to the RAD6A–(RAD18)2 complex
(Table 1 and Figure 6C). Again, the subunit composition
of the eluted fraction corresponded to RAD6A–(RAD18)2
(Figure 4B). These results strongly suggest ternary
complex formation in vivo.
BC
D
A
S. pombe      LVHCPACSNLVPHNQINQ-HLDSCLN
D. rerio      KVECPVCGVGVPEQHINK-HLDMCLN
G. gallus     KVDCPVCGVAIPEEYINK-HLDSCLS
M. musculus   KVSCPVCGVSIPENHINK-HLDSCLS
H. sapiens    KVDCPVCGVNIPESHINK-HLDSCLS
- S. cerevisiae MAQCPICQQFYPLKALEKTHLDECLT
*
D221A
*
C207F
-
S. pombe      LPKLTYALLSESKIRSKLSEMGLPTDGHKQLLQRRHAKWV
D. rerio      MPKLLYTLITVPKLKKMLKECHLSAQGNREQLTRRHQEFT
G. gallus     MPKVVYNLLSDRDLKKKLKEHGLSSHGSRQQLIKRHQEFV
M. musculus   LPKTVYNLLSDRDLKKKLKQYGLSVQGNKQQLIKRHQEFV
H. sapiens    LPKTVYNLLSDRDLKKKLKEHGLSIQGNKQQLIKRHQEFV
S. cerevisiae LPKINFTSMTQSQIKQKLSSLGLSTNGTRQNMIKRYNHYE
*  *
L260A/L265A
S. pombe      CLICHEYFRAPLIT-SCSHTFCSFCIRDYLREHPMCPACR
D. rerio      CPICFEFLNISMMT-QCSHNFCSLCIRKFLSYKLLCPVCN
G. gallus     CGICFDYFSIAVIIPQCSHNYCSLCIRKFLSYKTQCPTCC
M. musculus   CGICFEYFNIAVIIPQCSHNYCSLCIRKFLSYKTQCPTCC
H. sapiens    CGICFEYFNIAMIIPQCSHNYCSLCIRKFLSYKTQCPTCC
S. cerevisiae CHICKDFLKVPVLTP-CGHTFCSLCIRTHLNNQPNCPLCL
**
I50A/R51A
**
(F53A/L54A)
*
(C25A,C25S,C25F)
*
(C28S,C28F)
*
(I27A)
*
D221A
*
C207F
RING UBZ SAP R6BD
**
I50A/R51A Mutation
Mutant protein
Truncated protein
*   *
L260A/L265A
RAD18RING RAD18SAP
RAD18D221A
RAD18C207F
1 395 340 282 243 225 201 64 26 495
1
495
341
388
RAD18ΔC1
RAD18ΔC2
RAD18ΔC3
RAD18ΔN1
115
113
Figure 3. RAD18 mutants analyzed in this study. (A) Multiple alignments of the RING domains of human RAD18 and its orthologs. Mutants
analyzed in this study are shown below the alignments. Mutants shown in parentheses were eluted in void volumes of gel ﬁltration chromatography.
(B) Multiple alignments of UBZ of human RAD18 and its orthologs. (C) Multiple alignments of the SAP domains of human RAD18 and its
orthologs. (D) Schematic representations of the structures of RAD18. Positions of the mutations are shown with designated names of the mutant
proteins.
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activity
Our system to purify RAD6–RAD18 complex with two
different tags is a useful tool for analysis of structure–
function relationships in RAD18. First, we applied this
system to test whether UBZ is required for dimerization of
RAD18 using two loss-of-function mutants, RAD18
C207F
and RAD18
D221A (34,37) (Figure 3B and D). The results
demonstrated that these mutants were successfully recon-
stituted into the complexes, RAD6A–(RAD18
C207F)2 and
RAD6A–(RAD18
D221A)2 (Figure 5A) and their ligase
activities were similar to that of wild-type complex
(Figure 5B). These results indicate UBZ to be dispensable
for complex formation and ligase activity, in line with
recent reports (15,39), demonstrating reliability of our
system for analysis of the structure and function of
RAD6–RAD18 complexes.
Functional interaction between RAD6 and the RING
domains of the two subunits of RAD18 in the complex
Next, we addressed the question whether the N-terminal
part containing a RING domain mediates dimerization.
We generated another truncated RAD18 mutant con-
sisting of the 1–115 amino acid residues of RAD18 (here-
after designated as RAD18
C3, Figure 3D). When
HisRAD18
C3 and
FLAGRAD18
C3 were co-produced
with RAD6A in the same E. coli cells, we found the
HisRAD18
C3-
FLAGRAD18
C3 dimer to be reconstituted,
but that RAD6A did not co-purify with the dimer. The
observed elution proﬁle of the dimer from a gel ﬁltration
column is shown in Figure 6A.
HisRAD18
C3 and
FLAGRAD18
C3, conﬁrmed by western blotting (Figure
6B), co-eluted with an apparent molecular mass of
 37kDa, slightly larger than the calculated molecular
mass of 29kDa as a dimer (Figure 6A and B). As a com-
plementary experiment, an N-terminal deletion mutant of
RAD18 consisting of 113–495 amino acid residues (here-
after designated as RAD18
N1, Figure 3D), was gene-
rated. When
HisRAD18
N1 was coproduced with
FLAGRAD18 and RAD6A,
HisRAD18
N1 co-puriﬁed with
RAD6A but not with
FLAGRAD18 (Figure 6D). As men-
tioned above, the RAD6A–(
HisRAD18–
FLAGRAD18)
ternary complex eluted at a position corresponding to
490kDa in gel ﬁltration (Figure 6C). In contrast, the
complex of RAD6A–
HisRAD18
N1 eluted at a position
corresponding to 220kDa, which is much smaller than
the ternary complex (Figure 6C). Furthermore the mo-
lecular ratio of RAD6A and
HisRAD18
N1 determined
by western blotting, compared with the ternary complex
as a reference, was close to 1:1 (Figure 6D). These results
suggest that the RAD6A–
HisRAD18
N1 complex is a
dimer composed of one RAD6A and one
HisRAD18
N1
molecule and imply that
HisRAD18
N1 neither self-
associates nor forms a heterodimer with
FLAGRAD18.
From these data shown in Figure 6, we conclude that
the N-terminal region (1–115) is necessary and sufﬁcient
for dimerization, while UBZ and SAP domains are
dispensable.
In general, the RING domains of E3s have an essential
function in ligase activity by mediating interactions with
E2s (1,2). It is of great interest to clarify how the two
RING domains interact with one RAD6 subunit in the
RAD6A–(RAD18)2 complex. To address this point, we
made several mutants in which one or two conserved
amino acid residues in the RING domain were replaced
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Figure 4. Ternary complex formation of RAD6A and RAD18 in vivo.( A)
HARAD6–
FLAGRAD18 complexes isolated from human cells were
analyzed by SDS–PAGE (lane 1) together with RAD6A–(RAD18)2 isolated from E. coli (lanes 2–4) followed by western blotting probed with
anti-RAD18 and anti-RAD6 antibodies. Relative chemiluminescence signals of
HARAD6A and
FLAGRAD18 (sum of unmodiﬁed
FLAGRAD18 and
Ub-
FLAGRAD18) detected with a CCD camera were plotted with those of RAD6A and RAD18 puriﬁed from E. coli as references. The theoretical
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1070 Nucleic Acids Research, 2012,Vol.40, No. 3as indicated in Figure 3A. We found that RING mutants
with C25A, C25S, C25F, I27A, C28S, C27F or F53A/
L54A substitutions eluted in void volumes on gel ﬁltration
chromatography, suggesting these mutants to form large
aggregates due to highly disordered structures by
misfolding. Therefore we did not further analyze them.
However, we could successfully obtain one mutant
complex containing I50A/R51A substitutions in RAD18
(hereafter designated as RAD18
RING, see Figures 3A
and 7A, lane 2). A previous report suggested, based on
the crystal structure of the c-Cbl-UbcH7 complex, that the
amino acid residues Ile50 and Arg51 of RAD18 should be
located in a predicted RAD6-interacting a-helix (2). Thus,
it was expected that I50A/R51A mutations would affect
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indicated antibodies.
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FLAGRAD18
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(
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FLAGRAD18) and RAD6A–
HisRAD18
N1 complexes from a Superdex 200 gel ﬁltration column. Respective complexes were eluted in
9.77 and 11.45ml, corresponding to 490 and 220kDa of the apparent molecular masses, and 62 and 52A ˚ of Stokes’ radius, estimated from a
standard curve of the marker proteins. (D) Peak fractions of gel ﬁltration chromatography (C) were analyzed by SDS–PAGE followed by CBB
staining and western blotting probed with the indicated antibodies. Relative chemiluminescence signals detected with a CCD camera are shown. Lane
1, RAD6A–(
HisRAD18–
FLAGRAD18) (3.7pmol as a trimer); lane 2, RAD6A–
HisRAD18
N1 (3.7pmol as a dimer).
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Figure 5. Analysis of ligase activity and complex formation with UBZ mutants of RAD18. (A) Puriﬁed complexes (3.7pmol) were analyzed by SDS–
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FLAGRAD18); II, RAD6A–(
HisRAD18
C207F–
FLAGRAD18
C207F); III, RAD6A–
(
HisRAD18
D221A–
FLAGRAD18
D221A). Structures are represented schematically, UBZ domains with a mutation being shown in white boxes. (B)
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Nucleic Acids Research,2012, Vol.40, No. 3 1071the ligase activity of RAD18. In fact, it was much re-
duced when compared to that of the wild-type
complex (Figure 7B). Then, we reconstituted a hetero
complex with the mutant and wild-type, RAD6A–
(
HisRAD18
RING–
FLAGRAD18) (Figure 7A, lane 3).
Surprisingly, its ligase activity was essentially identical to
that of the wild-type (Figure 7B), indicating that an inter-
action between RAD6 and only one RING domain in
the two RAD18 subunits is sufﬁcient for ligase activity.
In addition, I50A/R51A mutations were combined with
the C1 mutation and two mutant complexes, RAD6A–
(
HisRAD18
RING–
FLAGRAD18
C1) and RAD6A–
(
HisRAD18
RING/C1–
FLAGRAD18) were reconstituted
(Figure 7C). Analysis of their ligase activities demonst-
rated these to be as active as the wild-type (Figure 7D),
indicating that one RAD6 molecule in the complex has the
potential to interact with either subunit of the RAD18
dimer.
Functional interaction between SAP and R6BD for ligase
activity
It has been shown that the SAP domain of RAD18 has
DNA-binding activity (15,38), which is separable from its
essential function for ligase activity (38). When a mutant
RAD18 containing L250A/L265A substitutions (hereafter
designated as RAD18
SAP, see Figure 3D) was successfully
reconstituted into the ternary complex, RAD6A–
(
HisRAD18
SAP–
FLAGRAD18
SAP) (Figure 8A, lane 2), the
ligase activity of the mutant complex was reduced to
an undetectable level (Figure 8B). However, activity was
restored in a hetero complex with the wild-type, RAD6A–
(
HisRAD18
SAP–
FLAGRAD18) (Figure 8B), demonstrating
that only one of the two SAP domains in the complex
is sufﬁcient for the essential SAP function. Next, the
SAP mutation was combined with the C1 mutation to
reconstitute RAD6A–(
HisRAD18
SAP–
FLAGRAD18
C1)
and RAD6–(
HisRAD18
SAP/C1–
FLAGRAD18) (Figure 8C).
Interestingly, the former had quite reduced ligase activity,
but the latter exhibited the wild-type level (Figure 8D),
indicating that the active SAP domain should be present
on the same RAD18 molecule to which RAD6 binds. In
contrast, such functional interaction was not observed
between RING and SAP mutants; ligase activities of
RAD6A–(
HisRAD18
RING/SAP–
FLAGRAD18) and RAD6–
(
HisRAD18
RING–
FLAGRAD18
SAP) complexes (Figure 8E)
were similar to that of wild-type (Figure 8F).
DISCUSSION
In this study, we established a method to distinguish
between the two subunits of RAD18 in the RAD6–
(RAD18)2 complex by introducing different tags at the
N-termini. This enabled us to purify RAD18 complexes
composed of wild–wild, wild–mutant or mutant–mutant
subunits and facilitated analysis of structure–function re-
lationships in RAD18.
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1072 Nucleic Acids Research, 2012,Vol.40, No. 3Previously, it was considered that the RAD6–RAD18
complex could be composed of two RAD6 and two
RAD18, since the observations that RAD18 binds to
RAD6 and it forms a dimer led to the assumption that
each RAD18 molecule in the dimer should bind to RAD6
(15,20,21). However, there is little evidence for such an
assignment based on the stoichiometry of RAD6. In this
study, we provided hard lines of evidence that the complex
is composed of one subunit of RAD6 and two subunits of
RAD18, so that the overall structure of the ternary
complex should be asymmetric.
The RING domains in E3s have an essential function in
ligase activity by mediating interactions with E2s. Zheng
et al. (2) have suggested, on the basis of the crystal struc-
ture of the c-Cbl-UbcH7 complex, that amino acid
residues I50 and R51 in the RING domain of RAD18
are located in a predicted RAD6-interacting a-helix.
Consistent with this, a mutant complex containing I50A/
R51A substitutions in both RAD18 subunits exhibited
severely reduced ligase activity, probably due to an
impaired interaction between the altered RING domain
and RAD6A. When the mutant subunit was complexed
with wild-type RAD18 subunit, ligase activity was
restored to the wild-type level, indicating that only one
of the two RING domains is necessary for enzyme
function. Furthermore, even when the RING mutation
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Nucleic Acids Research,2012, Vol.40, No. 3 1073was combined with a deletion mutation of R6BD in the
same or other RAD18 subunit, the complexes exhibited
robust ligase activity. These results imply that RAD6 can
bind in either one of the two R6BDs, then interacting with
one of the two RING domains in the RAD18 dimer.
Why should the RING domain of RAD18 form a
dimer? We found that inactivation of one RING domain
does not affect the ligase activity, indicating that the close
proximity of two active RING domains in RAD18 is not
important for the enzyme function. From our observa-
tions that some RING mutants such as C25A, C25S,
C25F, I27A, C28S, C28F and F53A/L54A, probably dis-
rupting the RING structure (Figure 3D), appeared to
form large aggregates, we suggest that the RING structure
is required for stable dimerization, which is in turn neces-
sary for sustaining the functionally active RING structure
of RAD18. From the results, we cannot exclude the pos-
sibility of retention of some enzyme functions even in ag-
gregates. Indeed, it has been reported that the C28F
mutant can fully complement the homologous recombin-
ation defects of RAD18-null cells (39).
The SAP domain is a unique eukaryotic module
involved in sequence- or structure-speciﬁc DNA binding
(36,38,49–52). Additionally, in RAD18 it has an essential
role in ligase activity, separable from its function in DNA
binding (38). We further demonstrated that one of the two
SAP domains in the RAD6–(RAD18)2 complex is sufﬁ-
cient for ligase activity. Interestingly, experiments using
hetero complexes, in which mutation in the SAP domain
was combined with a deletion mutation of R6BD, revealed
an interesting relationship between SAP and R6BD.
Although one of the two SAP domains and one of the
two R6BDs are sufﬁcient for enzyme activity, the active
SAP domain should be present on the same RAD18
molecule to which RAD6 binds in the complex. It makes
a sharp contrast to the case of RING mutant as described
above. A simple explanation is that the SAP domain acts
as a hinge connecting the R6BD and RING domain to
enable precise juxtaposition between RING and RAD6.
This might be very important for ligase activity because a
deletion mutant of R6BD hardly supported PCNA
ubiquitination in the presence of an excess amount of
RAD6A, which should be high enough to detect ligase
activities for many other E2–E3 pairs (4–6,9–2). It seems
likely that binding afﬁnity between RAD6 and the RING
domain of RAD18 is very low. That could be the reason
why R6BD is essential for ligase activity of the RAD6–
RAD18 complex. The tight interaction between RAD6
and R6BD confers on the complex the ability to
monoubiquitinate PCNA, also inhibiting the activity of
RAD6 catalyzing ubiquitin chain formation (19).
In the above, we have shown that RAD6 and RAD18
forms a ternary complex, RAD6–(RAD18)2 and
demonstrated that one R6BD site is sufﬁcient for the
ligase activity. Then, a question that immediately arises
is why RAD6 can bind to one of the two R6BD sites,
but not to both of them. Although we have no experimen-
tal data to answer the question at the moment, such a case
is not unprecedented. CHIP (C-terminal of Hsp70
interacting protein), a protein containing a C-terminal
Ubox domain (similar to RING) and an N-terminal
TPR domain, forms an asymmetric dimer mediated by
the Ubox domains, in which only one of the two Ubox
domains is available for binding to E2 (Ubc13) because
the other Ubox domain is blocked due to interaction with
the TPR domain (53). It is tempting to speculate that a
segment including R6BD located in a C-terminal portion
of the two RAD18 subunits may interact with one of the
two RING domains, consequently preventing the R6BD
from interacting with RAD6. Thus, one RAD6 molecule
can bind to the other R6BD and is positioned closely to
another unoccupied RING domain for catalyzing the
ligase function. Evidently, further experiments are
required to elucidate this interesting possibility.
During the course of ﬁnally completing this manuscript,
we have learned that Huang and co-workers have recently
determined the structure of a RAD18 RING(1–99) dimer,
also showing that this binds to RAD6 at a 2:2 ratio,
whereas the full-length RAD18 dimer binds only to a
single RAD6 molecule (54). Our study was conducted in-
dependently of their work.
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